Diplomat Launches Month-Long Campaign to Honor Cancer Patients
FLINT, Mich. – June 6, 2016 – The nation’s largest independent specialty pharmacy launches a national multimedia campaign to recognize cancer patients and their caregivers.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is launching a month-long campaign to celebrate National Cancer Survivors Day and the people touched by the disease. The company also released a video highlighting one of their own patients’ personal stories and her experience with acute myeloid leukemia.
“Mallory’s story is a window into the life of a Diplomat patient,” said Diplomat chairman and CEO Phil Hagerman. “Our work is about helping people like Mallory and her family, in the hopes that one day they, too, will celebrate National Cancer Survivors Day.”
Cancer treatments can be complex, and patients need coordinated care to guide them through the process. Diplomat’s oncology program connects the entire health care team, providing expertise and personal support throughout the patient’s therapy.
Sunday, June 5 is National Cancer Survivors Day, an annual celebration of life recognized in hundreds of communities across the nation. On June 7, Diplomat will focus on the disease in its first online “Diplomat Dialogue,” the launch to a series of live conversations planned between patients and health care professionals. Each “Diplomat Dialogue” will explore the triumphs and struggles faced along the patient’s treatment journey.
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com